Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53

M. H. Qazilbash, X. Xiao, P. Seth, K. H. Cowan, C. E. Walsh

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Previous studies have indicated that transfer of wild-type (wt) p53 cDNA into cancer cells can suppress the tumor phenotype in vitro and in vivo. In this study we examined the effects of wt p53 transduction in the human cancer cell line H-358 (that bears a homozygous deletion of p53) using a novel recombinant adeno-associated viral vector engineered to express wt p53 (rAAVp53). Western blot analysis demonstrated the expression of wt p53 in H-358 cells following infection with rAAVp53. Furthermore, rAAVp53 inhibited the growth of the neoplastic cells and also mediated cytotoxicity. Cell cycle analysis of rAAVp53-infected cells showed a significant increase in the percentage of cells arrested at the G1-S checkpoint. H-358 cells infected with rAAVp53 underwent apoptosis as demonstrated by the morphological appearance of DAPI-stained nuclei. Direct injection of rAAVp53 into H-358 tumors implanted subcutaneously in immunodeficient nu/nu mice inhibited tumor growth completely in three of the five animals tested. Mock-infected and rAAV control treated nu/nu mice detected the presence of wild-type p53 protein in residual tumor cells following rAAVp53 administration. The impressive in vivo efficacy of the rAAVp53 suggests a bystander effect. We conclude that rAAV may be effective as a gene transfer vector in the delivery of p53 to cancer cells.

Original languageEnglish (US)
Pages (from-to)675-682
Number of pages8
JournalGene Therapy
Volume4
Issue number7
DOIs
StatePublished - Jan 1 1997

Fingerprint

Dependovirus
Neoplasm Genes
Genetic Therapy
Neoplasms
Bystander Effect
Residual Neoplasm
Growth
Cell Cycle
Complementary DNA
Western Blotting
Apoptosis
Phenotype
Cell Line
Injections
Infection

Keywords

  • Apoptosis
  • Cell cycle arrest
  • Gene therapy
  • P53
  • Recombinant adeno-associated virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. / Qazilbash, M. H.; Xiao, X.; Seth, P.; Cowan, K. H.; Walsh, C. E.

In: Gene Therapy, Vol. 4, No. 7, 01.01.1997, p. 675-682.

Research output: Contribution to journalArticle

Qazilbash, M. H. ; Xiao, X. ; Seth, P. ; Cowan, K. H. ; Walsh, C. E. / Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. In: Gene Therapy. 1997 ; Vol. 4, No. 7. pp. 675-682.
@article{9b229a019c534b30b29ff540f87aa0fe,
title = "Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53",
abstract = "Previous studies have indicated that transfer of wild-type (wt) p53 cDNA into cancer cells can suppress the tumor phenotype in vitro and in vivo. In this study we examined the effects of wt p53 transduction in the human cancer cell line H-358 (that bears a homozygous deletion of p53) using a novel recombinant adeno-associated viral vector engineered to express wt p53 (rAAVp53). Western blot analysis demonstrated the expression of wt p53 in H-358 cells following infection with rAAVp53. Furthermore, rAAVp53 inhibited the growth of the neoplastic cells and also mediated cytotoxicity. Cell cycle analysis of rAAVp53-infected cells showed a significant increase in the percentage of cells arrested at the G1-S checkpoint. H-358 cells infected with rAAVp53 underwent apoptosis as demonstrated by the morphological appearance of DAPI-stained nuclei. Direct injection of rAAVp53 into H-358 tumors implanted subcutaneously in immunodeficient nu/nu mice inhibited tumor growth completely in three of the five animals tested. Mock-infected and rAAV control treated nu/nu mice detected the presence of wild-type p53 protein in residual tumor cells following rAAVp53 administration. The impressive in vivo efficacy of the rAAVp53 suggests a bystander effect. We conclude that rAAV may be effective as a gene transfer vector in the delivery of p53 to cancer cells.",
keywords = "Apoptosis, Cell cycle arrest, Gene therapy, P53, Recombinant adeno-associated virus",
author = "Qazilbash, {M. H.} and X. Xiao and P. Seth and Cowan, {K. H.} and Walsh, {C. E.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1038/sj.gt.3300444",
language = "English (US)",
volume = "4",
pages = "675--682",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53

AU - Qazilbash, M. H.

AU - Xiao, X.

AU - Seth, P.

AU - Cowan, K. H.

AU - Walsh, C. E.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Previous studies have indicated that transfer of wild-type (wt) p53 cDNA into cancer cells can suppress the tumor phenotype in vitro and in vivo. In this study we examined the effects of wt p53 transduction in the human cancer cell line H-358 (that bears a homozygous deletion of p53) using a novel recombinant adeno-associated viral vector engineered to express wt p53 (rAAVp53). Western blot analysis demonstrated the expression of wt p53 in H-358 cells following infection with rAAVp53. Furthermore, rAAVp53 inhibited the growth of the neoplastic cells and also mediated cytotoxicity. Cell cycle analysis of rAAVp53-infected cells showed a significant increase in the percentage of cells arrested at the G1-S checkpoint. H-358 cells infected with rAAVp53 underwent apoptosis as demonstrated by the morphological appearance of DAPI-stained nuclei. Direct injection of rAAVp53 into H-358 tumors implanted subcutaneously in immunodeficient nu/nu mice inhibited tumor growth completely in three of the five animals tested. Mock-infected and rAAV control treated nu/nu mice detected the presence of wild-type p53 protein in residual tumor cells following rAAVp53 administration. The impressive in vivo efficacy of the rAAVp53 suggests a bystander effect. We conclude that rAAV may be effective as a gene transfer vector in the delivery of p53 to cancer cells.

AB - Previous studies have indicated that transfer of wild-type (wt) p53 cDNA into cancer cells can suppress the tumor phenotype in vitro and in vivo. In this study we examined the effects of wt p53 transduction in the human cancer cell line H-358 (that bears a homozygous deletion of p53) using a novel recombinant adeno-associated viral vector engineered to express wt p53 (rAAVp53). Western blot analysis demonstrated the expression of wt p53 in H-358 cells following infection with rAAVp53. Furthermore, rAAVp53 inhibited the growth of the neoplastic cells and also mediated cytotoxicity. Cell cycle analysis of rAAVp53-infected cells showed a significant increase in the percentage of cells arrested at the G1-S checkpoint. H-358 cells infected with rAAVp53 underwent apoptosis as demonstrated by the morphological appearance of DAPI-stained nuclei. Direct injection of rAAVp53 into H-358 tumors implanted subcutaneously in immunodeficient nu/nu mice inhibited tumor growth completely in three of the five animals tested. Mock-infected and rAAV control treated nu/nu mice detected the presence of wild-type p53 protein in residual tumor cells following rAAVp53 administration. The impressive in vivo efficacy of the rAAVp53 suggests a bystander effect. We conclude that rAAV may be effective as a gene transfer vector in the delivery of p53 to cancer cells.

KW - Apoptosis

KW - Cell cycle arrest

KW - Gene therapy

KW - P53

KW - Recombinant adeno-associated virus

UR - http://www.scopus.com/inward/record.url?scp=0030840093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030840093&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3300444

DO - 10.1038/sj.gt.3300444

M3 - Article

C2 - 9282168

AN - SCOPUS:0030840093

VL - 4

SP - 675

EP - 682

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 7

ER -